Co-Authors
This is a "connection" page, showing publications co-authored by SIJIE LU and GHEATH AL-ATRASH.
Connection Strength
0.673
-
Targeting the Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple Myeloma. Clin Cancer Res. 2018 07 15; 24(14):3386-3396.
Score: 0.158
-
A novel HLA-A*0201 restricted peptide derived from cathepsin G is an effective immunotherapeutic target in acute myeloid leukemia. Clin Cancer Res. 2013 Jan 01; 19(1):247-57.
Score: 0.108
-
Broad cross-presentation of the hematopoietically derived PR1 antigen on solid tumors leads to susceptibility to PR1-targeted immunotherapy. J Immunol. 2012 Dec 01; 189(11):5476-84.
Score: 0.108
-
The role of antigen cross-presentation from leukemia blasts on immunity to the leukemia-associated antigen PR1. J Immunother. 2012 May; 35(4):309-20.
Score: 0.104
-
Common minor histocompatibility antigen discovery based upon patient clinical outcomes and genomic data. PLoS One. 2011; 6(8):e23217.
Score: 0.099
-
Breast cancer cell uptake of the inflammatory mediator neutrophil elastase triggers an anticancer adaptive immune response. Cancer Res. 2012 Jul 01; 72(13):3153-62.
Score: 0.026
-
An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells. Blood. 2011 Apr 21; 117(16):4262-72.
Score: 0.024
-
Adoptive transfer of PR1 cytotoxic T lymphocytes associated with reduced leukemia burden in a mouse acute myeloid leukemia xenograft model. Cytotherapy. 2010 Dec; 12(8):1056-62.
Score: 0.023
-
PR1-specific T cells are associated with unmaintained cytogenetic remission of chronic myelogenous leukemia after interferon withdrawal. PLoS One. 2010 Jul 26; 5(7):e11770.
Score: 0.023